R&D Projects

BLI-O

Development of molecular markers to identify long survivors with immunotherapy

Cancer is the leading cause of death in Europe with over 3 million new cases and 1.7 million deaths each year. Among the different types of cancer with a high incidence in the population are non-small cell lung cancer, metastatic melanoma, and skin cancer. For each of these there are different types of treatment, but none of them are able to increase patient survival rates. Hodgkin’s lymphoma is a rare disease and its treatment consists of chemotherapy with or without radiotherapy on affected lymph node regions, with the percentage of people who do not respond to chemotherapy being very high and they have a poor prognosis for the disease.

In recent years, a high level of efficacy has been observed in the oncological treatment of advanced tumours through immunotherapy, despite not obtaining satisfactory results in clinical trials to date. As a result, it is considered vitally important to continue research into treatment with the aim of significantly increasing the survival rates of cancer patients.

3 mill

new cancer cases per year in Europe

detailGrey

Cancer is the leading cause of death in Europe, with 1.7 million deaths each year.

For this reason, the technological challenge of this project is to develop a molecular signature capable of identifying long-term survivors treated with immunotherapy, which is currently impossible to predict.

To achieve the objectives

Expediente: RTC2019-007359-1 2020-2023

To ensure the success of the project, Atrys Health S.A. collaborates with the Foundation for Biomedical Research of the Puerta de Hierro University Hospital, specifically with the Lung Cancer group of IDIPHISA, coordinated by Prof Dr Mariano Provencio.

This project has been funded by the Ministry of Science, Innovation, and Universities within the CHALLENGES-COLLABORATION Sub-programme, 2019 Call. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research.

Financial backers

Related projects

eDSalud

eDSalud

Plataforma de telemedicina multiespecialidad

Read more
TheraYAP

TheraYAP

Abordaje para el tratamiento personalizado de pacientes con cáncer a través del inhibidor YAP-TEAD

Read more
PRECISESADS

PRECISESADS

Reclasificación molecular para hallar biomarcadores útiles en enfermedades autoinmunes

Read more